The groundbreaking success of the copyright undeniably revolutionized the pharmaceutical landscape, but investing in companies primarily reliant on off-patent versions presents a uncertain picture. Although read more early returns were impressive, the expiration of patents and the emergence of less expensive alternatives have weakened the customer